Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 17-18/2013

01.09.2013 | main topic

Renale Osteodystrophie

verfasst von: Daniel Cejka, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 17-18/2013

Einloggen, um Zugang zu erhalten

Summary

The incidence of renal osteodystrophy (ROD) increases with deteriorating kidney function, affecting virtually every patient on chronic dialysis treatment. ROD can persist after kidney transplantation and may be aggravated by immunosuppressants, mainly glucocorticoids. Fracture risk, including hip fractures, is markedly elevated in patients with renal disease compared to the general population. Depending on the type of ROD, high or low bone turnover can be found. Because of poor positive and negative predictive values of serological markers of bone turnover and limited technical capabilities of various bone imaging modalities, the only reliable method to correctly classify ROD is the transiliac bone biopsy. Elevated bone turnover can be successfully treated with active vitamin D, cinacalcet, or parathyreoidectomy, but all of these therapies may lead to oversuppression of bone metabolism. Currently, no specific therapy is available for low turnover bone disease. Bisphosphonates can be a therapeutic option for selected patients after renal transplantation.
Literatur
1.
Zurück zum Zitat Moe S, Drüeke T, Block G, Cannata-Andia J, Elder G, Fukagawa M, et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009 Aug 1;76(S 113):S1–130. Moe S, Drüeke T, Block G, Cannata-Andia J, Elder G, Fukagawa M, et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009 Aug 1;76(S 113):S1–130.
2.
Zurück zum Zitat Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011 Apr;6(4):913–21.PubMedCrossRef Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011 Apr;6(4):913–21.PubMedCrossRef
3.
Zurück zum Zitat Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999 Dec 2;341(23):1725–30.PubMedCrossRef Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999 Dec 2;341(23):1725–30.PubMedCrossRef
4.
Zurück zum Zitat Lehmann G, Ott U, Stein G, Steiner T, Wolf G. Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant Proc. 2007 Dec;39(10):3153–8.PubMedCrossRef Lehmann G, Ott U, Stein G, Steiner T, Wolf G. Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant Proc. 2007 Dec;39(10):3153–8.PubMedCrossRef
5.
Zurück zum Zitat Kodras K, Haas M. Effect of kidney transplantation on bone. Eur J Clin Invest. 2006 Aug;36 (Suppl 2):63–75.PubMedCrossRef Kodras K, Haas M. Effect of kidney transplantation on bone. Eur J Clin Invest. 2006 Aug;36 (Suppl 2):63–75.PubMedCrossRef
6.
Zurück zum Zitat Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006 Apr 26;69(11):1945–53.PubMedCrossRef Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006 Apr 26;69(11):1945–53.PubMedCrossRef
7.
Zurück zum Zitat Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995 Oct;26(4):622–31.PubMedCrossRef Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995 Oct;26(4):622–31.PubMedCrossRef
8.
Zurück zum Zitat Herberth J, Monier-Faugere MC, Mawad HW, Branscum AJ, Herberth Z, Wang G, et al. The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients. Clin Nephrol. 2009 Jul;72(1):5–14.PubMedCrossRef Herberth J, Monier-Faugere MC, Mawad HW, Branscum AJ, Herberth Z, Wang G, et al. The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients. Clin Nephrol. 2009 Jul;72(1):5–14.PubMedCrossRef
9.
Zurück zum Zitat Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, et al. Downregulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int. 2000 Oct;58(4):1440–9.PubMedCrossRef Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, et al. Downregulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int. 2000 Oct;58(4):1440–9.PubMedCrossRef
10.
Zurück zum Zitat Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000 Aug;58(2):753–61.PubMed Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000 Aug;58(2):753–61.PubMed
11.
Zurück zum Zitat Duursma SA, Visser WJ, Mees EJ, Njio L. Serum calcium, phosphate and alkaline phosphatase and morphometric bone examinations in 30 patients with renal insufficiency. Calcif Tissue Res. 1974;16(2):129–38.PubMedCrossRef Duursma SA, Visser WJ, Mees EJ, Njio L. Serum calcium, phosphate and alkaline phosphatase and morphometric bone examinations in 30 patients with renal insufficiency. Calcif Tissue Res. 1974;16(2):129–38.PubMedCrossRef
12.
Zurück zum Zitat Couttenye MM, D’Haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in hemodialysis patients. Nephrol Dial Transplant. 1996 Jun 1;11(6):1065–72.PubMedCrossRef Couttenye MM, D’Haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in hemodialysis patients. Nephrol Dial Transplant. 1996 Jun 1;11(6):1065–72.PubMedCrossRef
13.
Zurück zum Zitat Malluche HH, Faugere MC, Fanti P, Price PA. Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int. 1984 Dec;26(6):869–74.PubMedCrossRef Malluche HH, Faugere MC, Fanti P, Price PA. Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int. 1984 Dec;26(6):869–74.PubMedCrossRef
14.
Zurück zum Zitat Coen G, Mazzaferro S, Ballanti P, Bonucci E, Bondatti F, Manni M, et al. Procollagen type I C-terminal extension peptide in predialysis chronic renal failure. Am J Nephrol. 1992;12(4):246–51.PubMedCrossRef Coen G, Mazzaferro S, Ballanti P, Bonucci E, Bondatti F, Manni M, et al. Procollagen type I C-terminal extension peptide in predialysis chronic renal failure. Am J Nephrol. 1992;12(4):246–51.PubMedCrossRef
15.
Zurück zum Zitat Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E, et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis. 2002 Oct;40(4):802–9.PubMedCrossRef Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E, et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis. 2002 Oct;40(4):802–9.PubMedCrossRef
16.
Zurück zum Zitat Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Domenig C, et al. Osteoprotegerin and parathyroid hormone as markers of high turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis. 2002 Mar;39(3):580–6.PubMedCrossRef Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Domenig C, et al. Osteoprotegerin and parathyroid hormone as markers of high turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis. 2002 Mar;39(3):580–6.PubMedCrossRef
17.
Zurück zum Zitat Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011 Apr;6(4):877–82.PubMedCrossRef Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011 Apr;6(4):877–82.PubMedCrossRef
18.
Zurück zum Zitat Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol. 2000 Nov;13(6):437–43.PubMed Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol. 2000 Nov;13(6):437–43.PubMed
19.
Zurück zum Zitat Lindergard B, Johnell O, Nilsson BE, Wiklund PE. Studies of bone morphology, bone densitometry and laboratory data in patients on maintenance hemodialysis treatment. Nephron. 1985;39(2):122–9.PubMedCrossRef Lindergard B, Johnell O, Nilsson BE, Wiklund PE. Studies of bone morphology, bone densitometry and laboratory data in patients on maintenance hemodialysis treatment. Nephron. 1985;39(2):122–9.PubMedCrossRef
20.
Zurück zum Zitat Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a metaanalysis. Am J Kidney Dis. 2007 May;49(5):674–81.PubMedCrossRef Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a metaanalysis. Am J Kidney Dis. 2007 May;49(5):674–81.PubMedCrossRef
21.
Zurück zum Zitat Smith JA, Vento JA, Spencer RP, Tendler BE. Aortic calcification contributing to bone densitometry measurement. J Clin Densitom. 1999;2(2):181–3.PubMedCrossRef Smith JA, Vento JA, Spencer RP, Tendler BE. Aortic calcification contributing to bone densitometry measurement. J Clin Densitom. 1999;2(2):181–3.PubMedCrossRef
22.
Zurück zum Zitat Jamal SA, Gilbert J, Gordon C, Bauer DC. Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res. 2006 Apr;21(4):543–8.PubMedCrossRef Jamal SA, Gilbert J, Gordon C, Bauer DC. Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res. 2006 Apr;21(4):543–8.PubMedCrossRef
23.
Zurück zum Zitat Amling M, Herden S, Posl M, Hahn M, Ritzel H, Delling G. Heterogeneity of the skeleton: comparison of the trabecular microarchitecture of the spine, the iliac crest, the femur, and the calcaneus. J Bone Miner Res. 1996 Jan;11(1):36–45.PubMedCrossRef Amling M, Herden S, Posl M, Hahn M, Ritzel H, Delling G. Heterogeneity of the skeleton: comparison of the trabecular microarchitecture of the spine, the iliac crest, the femur, and the calcaneus. J Bone Miner Res. 1996 Jan;11(1):36–45.PubMedCrossRef
24.
Zurück zum Zitat Cejka D, Patsch JM, Weber M, Diarra D, Riegersperger M, Kikic Z, et al. Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol. 2011 Sep;6(9):2264–71. (Epub 2011 Jul 7)PubMedCrossRef Cejka D, Patsch JM, Weber M, Diarra D, Riegersperger M, Kikic Z, et al. Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol. 2011 Sep;6(9):2264–71. (Epub 2011 Jul 7)PubMedCrossRef
25.
Zurück zum Zitat Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger P. Changes in bone mass early after kidney transplantation. J Bone Miner Res. 1994 Jan;9(1):1–9.PubMedCrossRef Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger P. Changes in bone mass early after kidney transplantation. J Bone Miner Res. 1994 Jan;9(1):1–9.PubMedCrossRef
26.
Zurück zum Zitat Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis. 1996 Jul;28(1):105–14.PubMedCrossRef Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis. 1996 Jul;28(1):105–14.PubMedCrossRef
27.
Zurück zum Zitat Cueto-Manzano AM, Konel S, Freemont AJ, Adams JE, Mawer B, Gokal R, et al. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis. 2000 Feb;35(2):227–36.PubMedCrossRef Cueto-Manzano AM, Konel S, Freemont AJ, Adams JE, Mawer B, Gokal R, et al. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis. 2000 Feb;35(2):227–36.PubMedCrossRef
28.
Zurück zum Zitat Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski M, Exner VM, et al. Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant. 1995 Nov;10(11):2096–100.PubMed Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski M, Exner VM, et al. Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant. 1995 Nov;10(11):2096–100.PubMed
29.
Zurück zum Zitat Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991 Aug 22;325(8):544–50.PubMedCrossRef Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991 Aug 22;325(8):544–50.PubMedCrossRef
30.
Zurück zum Zitat Cueto-Manzano AM, Konel S, Hutchison AJ, Crowley V, France MW, Freemont AJ, et al. Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int. 1999 May;55(5):2021–9.PubMedCrossRef Cueto-Manzano AM, Konel S, Hutchison AJ, Crowley V, France MW, Freemont AJ, et al. Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int. 1999 May;55(5):2021–9.PubMedCrossRef
31.
Zurück zum Zitat Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation. 1994 Oct 27;58(8):912–5.PubMedCrossRef Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation. 1994 Oct 27;58(8):912–5.PubMedCrossRef
32.
Zurück zum Zitat Akaberi S, Simonsen O, Lindergard B, Nyberg G. Can DXA predict fractures in renal transplant patients? Am J Transplant. 2008 Dec;8(12):2647–51.PubMedCrossRef Akaberi S, Simonsen O, Lindergard B, Nyberg G. Can DXA predict fractures in renal transplant patients? Am J Transplant. 2008 Dec;8(12):2647–51.PubMedCrossRef
33.
Zurück zum Zitat Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000 Jul;58(1):396–9.PubMedCrossRef Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000 Jul;58(1):396–9.PubMedCrossRef
34.
Zurück zum Zitat Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int. 2006 Oct;70(7):1358–66.PubMedCrossRef Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int. 2006 Oct;70(7):1358–66.PubMedCrossRef
35.
Zurück zum Zitat National Institutes of Health NIoDaDaKDBM. U.S. Renal data system, USRDS 2010 National Institutes of Health NIoDaDaKDBM. U.S. Renal data system, USRDS 2010
36.
Zurück zum Zitat Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis. 2004 Oct;44(4):672–9.PubMed Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis. 2004 Oct;44(4):672–9.PubMed
37.
Zurück zum Zitat Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA. 2002 Dec 18;288(23):3014–8.PubMedCrossRef Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA. 2002 Dec 18;288(23):3014–8.PubMedCrossRef
38.
Zurück zum Zitat Abbott KC, Oglesby RJ, Hypolite IO, Kirk AD, Ko CW, Welch PG, et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol. 2001 Oct;11(7):450–7.PubMedCrossRef Abbott KC, Oglesby RJ, Hypolite IO, Kirk AD, Ko CW, Welch PG, et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol. 2001 Oct;11(7):450–7.PubMedCrossRef
39.
Zurück zum Zitat London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all cause and cardiovascular mortality. Nephrol Dial Transplant. 2003 Sep;18(9):1731–40.PubMedCrossRef London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all cause and cardiovascular mortality. Nephrol Dial Transplant. 2003 Sep;18(9):1731–40.PubMedCrossRef
40.
Zurück zum Zitat Okuno S, Ishimura E, Kitatani K, Fujino Y, Kohno K, Maeno Y, et al. Presence of abdominal aortic calcification is significantly associated with all cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2007 Mar;49(3):417–25.PubMedCrossRef Okuno S, Ishimura E, Kitatani K, Fujino Y, Kohno K, Maeno Y, et al. Presence of abdominal aortic calcification is significantly associated with all cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2007 Mar;49(3):417–25.PubMedCrossRef
41.
Zurück zum Zitat Pirklbauer M, Mayer G. The exchangeable calcium pool: physiology and pathophysiology in chronic kidney disease. Nephrol Dial Transplant. 2011 Aug;26(8):2438–44.PubMedCrossRef Pirklbauer M, Mayer G. The exchangeable calcium pool: physiology and pathophysiology in chronic kidney disease. Nephrol Dial Transplant. 2011 Aug;26(8):2438–44.PubMedCrossRef
42.
Zurück zum Zitat London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004 Jul;15(7):1943–51.PubMedCrossRef London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004 Jul;15(7):1943–51.PubMedCrossRef
43.
Zurück zum Zitat London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008 Sep;19(9):1827–35.PubMedCrossRef London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008 Sep;19(9):1827–35.PubMedCrossRef
44.
Zurück zum Zitat Asci G, Ok E, Savas R, Ozkahya M, Duman S, Toz H, et al. The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol Dial Transplant. 2011 Mar;26(3):1010–5. (Epub 2010 Aug 13)PubMedCrossRef Asci G, Ok E, Savas R, Ozkahya M, Duman S, Toz H, et al. The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol Dial Transplant. 2011 Mar;26(3):1010–5. (Epub 2010 Aug 13)PubMedCrossRef
45.
Zurück zum Zitat Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001 Jul;12(7):1530–7.PubMed Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001 Jul;12(7):1530–7.PubMed
46.
Zurück zum Zitat Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 2003 Mar;63(3):1130–6.PubMedCrossRef Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 2003 Mar;63(3):1130–6.PubMedCrossRef
47.
Zurück zum Zitat Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003 Oct;14(10):2669–76.PubMedCrossRef Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003 Oct;14(10):2669–76.PubMedCrossRef
48.
Zurück zum Zitat Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005015. Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005015.
49.
Zurück zum Zitat Andress DL, Maloney NA, Endres DB, Sherrard DJ. Aluminum associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population. J Bone Miner Res. 1986 Oct;1(5):391–8.PubMedCrossRef Andress DL, Maloney NA, Endres DB, Sherrard DJ. Aluminum associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population. J Bone Miner Res. 1986 Oct;1(5):391–8.PubMedCrossRef
50.
Zurück zum Zitat Andress DL, Nebeker HG, Ott SM, Endres DB, Alfrey AC, Slatopolsky EA, et al. Bone histologic response to deferoxamine in aluminum related bone disease. Kidney Int. 1987 Jun;31(6):1344–50.PubMedCrossRef Andress DL, Nebeker HG, Ott SM, Endres DB, Alfrey AC, Slatopolsky EA, et al. Bone histologic response to deferoxamine in aluminum related bone disease. Kidney Int. 1987 Jun;31(6):1344–50.PubMedCrossRef
51.
Zurück zum Zitat KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009 Aug;(113):S1–130. 130. doi: 10.1038/ki.2009.188. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009 Aug;(113):S1–130. 130. doi: 10.1038/ki.2009.188.
52.
Zurück zum Zitat Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008 Feb;19(2):405–12.PubMedCrossRef Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008 Feb;19(2):405–12.PubMedCrossRef
53.
Zurück zum Zitat D’Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003 Jun;(85):S73–8. D’Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003 Jun;(85):S73–8.
54.
Zurück zum Zitat Baker LR, Abrams SM, Roe CJ, Faugere MC, Fanti P, Subayti Y, et al. Early therapy of renal bone disease with calcitriol: a prospective double blind study. Kidney Int Suppl. 1989 Nov;27:S140–2. Baker LR, Abrams SM, Roe CJ, Faugere MC, Fanti P, Subayti Y, et al. Early therapy of renal bone disease with calcitriol: a prospective double blind study. Kidney Int Suppl. 1989 Nov;27:S140–2.
55.
Zurück zum Zitat Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab. 1988 Nov;67(5):929–36.PubMedCrossRef Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab. 1988 Nov;67(5):929–36.PubMedCrossRef
56.
Zurück zum Zitat Baker LR, Muir JW, Sharman VL, Abrams SM, Greenwood RN, Cattell WR, et al. Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol. 1986 Oct;26(4):185–91.PubMed Baker LR, Muir JW, Sharman VL, Abrams SM, Greenwood RN, Cattell WR, et al. Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol. 1986 Oct;26(4):185–91.PubMed
57.
Zurück zum Zitat Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med. 1989 Aug 3;321(5):274–9.PubMedCrossRef Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med. 1989 Aug 3;321(5):274–9.PubMedCrossRef
58.
Zurück zum Zitat Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995 Feb 11;310(6976):358–63.PubMedCrossRef Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995 Feb 11;310(6976):358–63.PubMedCrossRef
59.
Zurück zum Zitat Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor 23 in secondary hyperparathyroidism. Kidney Int. 2011 Jan;79(1):112–9.PubMedCrossRef Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor 23 in secondary hyperparathyroidism. Kidney Int. 2011 Jan;79(1):112–9.PubMedCrossRef
60.
Zurück zum Zitat Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998 Aug;9(8):1427–32.PubMed Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998 Aug;9(8):1427–32.PubMed
61.
Zurück zum Zitat Hayashi M, Tsuchiya Y, Itaya Y, Takenaka T, Kobayashi K, Yoshizawa M, et al. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Nephrol Dial Transplant. 2004 Aug;19(8):2067–73.PubMedCrossRef Hayashi M, Tsuchiya Y, Itaya Y, Takenaka T, Kobayashi K, Yoshizawa M, et al. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Nephrol Dial Transplant. 2004 Aug;19(8):2067–73.PubMedCrossRef
62.
Zurück zum Zitat de Sevaux RGL, Hoitsma AJ, Corstens FHM, Wetzels JFM. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol. 2002 Jun 1;13(6):1608–14.PubMedCrossRef de Sevaux RGL, Hoitsma AJ, Corstens FHM, Wetzels JFM. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol. 2002 Jun 1;13(6):1608–14.PubMedCrossRef
63.
Zurück zum Zitat El-Agroudy AE, El-Husseini AA, El-Sayed M, Ghoneim MA. Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol. 2003 Nov 1;14(11):2975–9.PubMedCrossRef El-Agroudy AE, El-Husseini AA, El-Sayed M, Ghoneim MA. Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol. 2003 Nov 1;14(11):2975–9.PubMedCrossRef
64.
Zurück zum Zitat Koc M, Tuglular S, Arikan H, Ozener C, Akoglu E. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc. 2002 Sep;34(6):2111–3.PubMedCrossRef Koc M, Tuglular S, Arikan H, Ozener C, Akoglu E. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc. 2002 Sep;34(6):2111–3.PubMedCrossRef
65.
Zurück zum Zitat Nam JH, Moon JI, Chung SS, Kim SI, Park KI, Song YD, et al. Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation. Transplant Proc. 2000 Nov;32(7):1876.PubMedCrossRef Nam JH, Moon JI, Chung SS, Kim SI, Park KI, Song YD, et al. Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation. Transplant Proc. 2000 Nov;32(7):1876.PubMedCrossRef
66.
Zurück zum Zitat El-Husseini AA, El-Agroudy AE, El-Sayed M, Sobh MA, Ghoneim MA. A prospective randomized study for the treatment of bone loss with vitamin d during kidney transplantation in children and adolescents. Am J Transplant. 2004 Dec;4(12):2052–7.PubMedCrossRef El-Husseini AA, El-Agroudy AE, El-Sayed M, Sobh MA, Ghoneim MA. A prospective randomized study for the treatment of bone loss with vitamin d during kidney transplantation in children and adolescents. Am J Transplant. 2004 Dec;4(12):2052–7.PubMedCrossRef
67.
Zurück zum Zitat Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D. A controlled study of vitamin D3 to prevent bone loss in renal transplant patients receiving low doses of steroids. Transplantation. 2005 Jan 15;79(1):108–15.PubMedCrossRef Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D. A controlled study of vitamin D3 to prevent bone loss in renal transplant patients receiving low doses of steroids. Transplantation. 2005 Jan 15;79(1):108–15.PubMedCrossRef
68.
Zurück zum Zitat Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. 1994 Oct;46(4):1160–6.PubMedCrossRef Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. 1994 Oct;46(4):1160–6.PubMedCrossRef
69.
Zurück zum Zitat Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2008 Apr;69(4):269–78.PubMedCrossRef Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2008 Apr;69(4):269–78.PubMedCrossRef
70.
Zurück zum Zitat Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68(4):1793–800.PubMedCrossRef Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68(4):1793–800.PubMedCrossRef
71.
Zurück zum Zitat Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–94. (Epub 2012 Nov 6)PubMedCrossRef Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–94. (Epub 2012 Nov 6)PubMedCrossRef
72.
Zurück zum Zitat Cejka D, Kodras K, Bader T, Haas M. Treatment of hemodialysis associated adynamic bone disease with teriparatide (PTH(1–34)): a pilot study. Kidney Blood Press Res. 2010 Jun 24;33(3):221–6.PubMedCrossRef Cejka D, Kodras K, Bader T, Haas M. Treatment of hemodialysis associated adynamic bone disease with teriparatide (PTH(1–34)): a pilot study. Kidney Blood Press Res. 2010 Jun 24;33(3):221–6.PubMedCrossRef
Metadaten
Titel
Renale Osteodystrophie
verfasst von
Daniel Cejka, MD
Publikationsdatum
01.09.2013
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 17-18/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-013-0195-3

Weitere Artikel der Ausgabe 17-18/2013

Wiener Medizinische Wochenschrift 17-18/2013 Zur Ausgabe